Is cholera disease associated with poverty?

Journal of Infection in Developing Countries

Volumn 3, Issue 6, 2009, Pages 408-411

  Talavera, Arturo ^a   Pérez, Ela M ^a  

^a FINLAY INSTITUTE   (Cuba)

Author keywords

Cholera; Developing countries; Income; Poverty

Indexed keywords

ARTICLE; CHOLERA; CORRELATIONAL STUDY; ECONOMIC ASPECT; INCIDENCE; MORBIDITY; MORTALITY; POVERTY;

EID: 73249131744     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.410     Document Type: Article

References (15)

1. World Health Organization (2008) "Cholera". WHO Fact sheet N̊ 107. Available: http://www.who.int/mediacentre/factsheets/fs107/en/ index.html.
2. Ackers ML, Quick RE, Drasbek CJ, Hutwagner L and Tauxe RV (1998) Are there national risk factors for epidemic cholera? The correlation between socioeconomic and demographic indices and cholera incidence in Latin America. Int J Epidemiol 27: 330-334.
3. Gerolomo M and Penna ML (2000) Cholera and living conditions. Brazil Rev Saude Publica 34: 342-347.
4. Constantin de Magny G, Murtugudde R, Sapiano MR, Nizam A, Brown CW, Busalacchi AJ, Yunus M, Nair GB, Gil AI, Lanata CF, Calkins J, Manna B, Rajendran K, Bhattacharya MK, Huq A, Sack RB and Colwell RR (2008) Environmental signatures associated with cholera epidemics. Proc Natl Acad Sci USA 105: 17676-17681.
5. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas MES, Lopez AL, Kim DR, Ali M, and John D. Clemens JD (2008) The High Burden of Cholera in Children: Comparison of Incidence from Endemic Areas in Asia and Africa. PLoS Negl Trop Dis 2: 173.
6. World Health Organization (2006) Oral cholera vaccine use in complex emergencies. What next? Available: http://www.who.int/cholera/publications/ choleravaccineemergencies2005.pdf.
7. Sánchez, JL and Holmgren J (1989) Recombinant system for overexpression of cholera toxin B Subunit in Vibrio cholerae as basis for vaccine development. Proc Natl Acad Sci.USA 86: 481-485
8. Anh DD, Canh DG, López AL, Thiem VD, Long PT, Son NH, Deen J, Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Holmgren J and Clemens J (2007) Safety and immunogenecity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25: 1149-1155.
9. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Alam MS, Zaman K, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD and Sack DA (2005) Ramdomized, controlled study of the safety and Immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 192: 573-579.
10. García L, Jidy MD, García H, Rodríguez BL, Fernández R, Año G, Cedré B, Valmaseda T, Suzarte E, Ramírez M, Pino Y, Campos J, Menéndez J, Valera R, González D, González I, Pérez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Pérez JL, Talavera A, Pérez A, Marrero K, Ledón T and Fando R (2005) The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 73: 3018-3024.
11. Schild S, Nelson EJ, Bishop AL and Camilli A (2009) Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun 77: 472-484.
12. Pérez JL, Acevedo R, Callicó A, Fernández Y, Cedré B, Año G, González L, Falero G, Talavera A, Pérez O and García L (2009) A proteoliposoma based formulation administrered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine 27: 205-212.
13. Talavera A, Año G, Pino Y, Castaño J, Uribarri E, Riverón L, Gil S, Fernández S, Cedré B, Valmaceda T, Pérez JL, Infante JF, García L and Sierra G (2006) Formulation in tablets of a cholera whole cells inactivated vaccine candidate Vaccine 24: 3381-3387.
14. World Health Organization (2008) Cholera 2007. Weekly Epidemiological Record 31: 269-284.
15. Zuckerman JN, Rombo L and Fisch A (2007) The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis. 7: 521-530.